Fc receptor News and Research

RSS

Placental biology breakthrough could make biologic medicines safer during pregnancy

Biologic medicines have transformed the treatment of cancer, autoimmune diseases, migraine, inflammatory disorders and many other diseases.

14 Aug 2026

Early RSV infection turns maternal allergy into a powerful driver of childhood asthma

Early-life RSV infection and parental allergy interact to substantially increase childhood asthma risk, supported by population data from more than 1.5 million children and mechanistic mouse experiments. The study shows that viral infection reprograms neonatal immune responses by altering how maternally transferred allergen-specific antibodies are handled, driving long-term allergic airway disease.

8 Dec 2025

Rockefeller scientists engineer next-generation antibody to replace IVIG therapy

Intravenous immunoglobulin (IVIG) therapy involves infusing patients with naturally occurring IgG antibodies to treat autoimmune conditions.

7 Nov 2025

New research reveals how human astroviruses enter the body

Human astroviruses are a leading viral cause of the stomach bug-think vomiting, diarrhea, and fever. It often impacts young children and older adults, leading to vicious cycles of sickness and malnutrition, particularly for those in low and middle income countries.

3 Nov 2025

Unlocking the secrets of vascular health through eye imaging

The tiny blood vessels in your eyes might hold the key to predicting a person's risk of developing heart disease and how fast they're biologically aging, according to researchers at McMaster University and Population Health Research Institute (PHRI) - a joint institute of Hamilton Health Sciences and McMaster.

24 Oct 2025

Rozanolixizumab prevents congenital heart block in high-risk pregnancy

Congenital heart block, sometimes referred to as cardiac neonatal lupus, is a rare but potentially life-threatening condition that affects babies born to mothers with specific autoantibodies - called anti-SSA/Ro antibodies - which can attack the fetal heart via its electrical conduction system, leading to a slower heart rate.

22 Oct 2025

How shifting antibodies fuel aging and the new therapies aiming to slow it

This review uncovers how aging reshapes immunoglobulins, particularly IgG, IgM, and IgA, driving inflammation, cellular senescence, and tissue degeneration. By dissecting B-cell dysfunction, glycosylation changes, and Fc receptor pathways, it reveals immunoglobulins as both biomarkers and potential therapeutic targets in aging.

14 Oct 2025

Researchers design factor IX variants for short- and long-term Hemophilia B management

After blood vessel damage, effective blood clotting is essential to halt bleeding. However, this process is inefficient in some individuals due to hereditary factors. Hemophilia B, for example, results from a deficiency in coagulation factor IX (FIX), which can lead to prolonged bleeding after injuries or surgery.

30 Sep 2025

Engineered CD40 antibody shrinks tumors and induces remission

Over the past 20 years, a class of cancer drugs called CD40 agonist antibodies have shown great promise-and induced great disappointment.

14 Aug 2025

Navigating the dual role of B cells in tumor immunity

B lymphocytes exhibit dual roles in tumorigenesis, acting as both allies and adversaries in the tumor microenvironment (TME).

3 Jun 2025

Critical protein linked to spillover potential of animal viruses

Scientists investigating animal viruses with potential to infect humans have identified a critical protein that could enable spillover of a family of organisms called arteriviruses.

1 Nov 2024

Octavalent intranasal flu vaccine proves effective in neutralizing both existing and emerging strains

A new octavalent intranasal vaccine shows promising results in providing broad immunity against both seasonal and pre-pandemic influenza strains by eliciting strong mucosal and systemic immune responses in ferrets.

25 Aug 2024

Study reveals how light-activated macrophages increase their appetite for cancer cells

The body has a veritable army constantly on guard to keep us safe from microscopic threats from infections to cancer.

12 Aug 2024

Proteomic signatures enhance risk prediction for both common and rare diseases

Researchers have developed sparse prediction models combining plasma proteins and clinical data to predict the 10-year risk of 218 diseases. The study, involving over 41,000 participants, highlights the enhanced predictive power of proteomic signatures.

24 Jul 2024

Study shows potential for universal flu vaccine with broad antibody response

Study discusses the potential of universal influenza vaccines, emphasizing the importance of antibody breadth and Fc receptor (FcR) effector functions in protecting against various influenza strains, including those with pandemic potential.

15 Apr 2024

Can yoga improve your prostate health?

The potential benefits of yoga in improving prostate health.

19 Jan 2024

Mice with humanized immune systems test new cancer therapeutic approach that blindfolds immune cells to the body’s self-recognition system

Researchers investigated the anticancer effects of drugs targeting human tumor-associated macrophages (TAMs) in vivo. In humanized murine models, they tested the effectiveness of an antibody to human signal regulatory protein alpha (SIRPα) for cancer immunotherapy.

19 Dec 2023

Proteomic study pinpoints potential biomarkers for long-COVID diagnosis and persistent health impacts

A two-year longitudinal study highlights proteomic changes in long-COVID patients, revealing potential biomarkers for diagnosis and shedding light on the persistent physiological challenges faced by survivors.

7 Nov 2023

New nasal vaccine for COVID-19 shows promise in animal studies

A team of University of Maryland researchers developed a nasal spray vaccine that delivers the SARS-CoV-2 spike protein into cells of the airway in mice and hamsters, triggering an immune response that significantly reduced infection and spread of COVID-19.

6 Nov 2023

Vaxzevria vaccine boosts mucosal immunity in COVID-19 recovered

Study highlights the ability of the Vaxzevria vaccine in inducing robust mucosal antibody responses, especially in COVID-19-recovered individuals, showcasing a notable defense against various SARS-CoV-2 variants. However, it emphasizes the need for booster doses to enhance anti-SARS-CoV-2 mucosal immunity, especially in infection-naïve individuals, to broaden protection against emerging viral variants.

28 Sep 2023